Purple Biotech gains U.S. patent for CAPTN-3
Rhea-AI Filing Summary
PURPLE BIOTECH LTD. (PPBT) reports that the U.S. Patent and Trademark Office has issued a Notice of Allowance for a patent application covering tri-specific antibody constructs and methods of use that support its proprietary CAPTN-3 platform for conditionally activated multispecific antibodies. This allowance strengthens protection for the modular architecture of CAPTN-3, which is designed to enable efficient generation of tri-specific antibodies by exchanging tumor-associated antigen binding domains and functional arms on a common backbone, potentially accelerating development of new oncology candidates. The platform’s lead candidate, IM1240, is advancing toward the clinic, while IM1305 is in preclinical development. The pipeline also includes additional clinical-stage assets CM24 and NT219, both of which have completed Phase 2 studies in difficult-to-treat cancers.
Positive
- None.
Negative
- None.
Filing Explained
The filing reports a Notice of Allowance for CAPTN-3 patent claims, meaning the USPTO found the allowed claims patentable but the patent is not yet issued: required issue fees still must be paid, so the added protection remains at the allowance stage.
Key Figures
Platform specificity: Tri-specific antibodies (3 binding specificities)
TAA binders per construct: 2 tumor-associated antigen binders
CM24 development stage: Phase 2 completed
+1 more
4 metrics
Platform specificity
Tri-specific antibodies (3 binding specificities)
CAPTN-3 platform designed to generate tri-specific antibody constructs
TAA binders per construct
2 tumor-associated antigen binders
Allowed claims cover tri-specific constructs comprising dual TAA binders
CM24 development stage
Phase 2 completed
CM24 demonstrated improved outcomes across all efficacy endpoints in a Phase 2 pancreatic cancer study
NT219 development stage
Phase 2 completed
NT219 completed a Phase 2 study in recurrent and/or metastatic squamous cell carcinoma of the head and neck
Key Terms
Notice of Allowance, tri-specific antibody constructs, tumor-associated antigen (TAA), tumor microenvironment, +2 more
6 terms
Notice of Allowance regulatory
"the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance"
A notice of allowance is an official confirmation from a patent office that a patent application has met all necessary requirements and is approved for granting. It signals that the invention is likely to receive legal protection soon, which can be important for investors considering the value and exclusivity of a new product or technology. Think of it as a green light indicating that the invention is on track to become legally protected.
tri-specific antibody constructs medical
"a patent application covering tri-specific antibody constructs and methods of use"
Engineered antibody molecules designed to bind three different targets or three distinct sites on cells or proteins, combining functions of multiple antibodies into a single therapeutic agent. Like a three-pronged tool that can grab or block multiple things at once, these constructs matter to investors because they represent a complex, higher-potential drug modality whose development, manufacturing and clinical testing profiles influence company pipelines, timelines, and regulatory risks.
tumor-associated antigen (TAA) medical
"exchanging tumor-associated antigen (TAA) binding domains and other functional arms"
tumor microenvironment medical
"Capping technology confines immune activation to the tumor microenvironment"
The tumor microenvironment is the immediate area surrounding a cancer cell, made up of nearby cells, blood vessels, and support structures that influence how the cancer grows and spreads. It functions like a bustling neighborhood that can either help or hinder the tumor’s development. For investors, understanding changes in this environment can signal the effectiveness of treatments and potential shifts in a cancer-related market.
therapeutic window medical
"significantly expanding the therapeutic window compared to conventional T-cell engagers"
The "therapeutic window" is the optimal range of a medication's dosage where it effectively treats a condition without causing harmful side effects. For investors, understanding this concept highlights the importance of balance—just as too little medication may be ineffective and too much can be dangerous, financial strategies or investments need to be carefully managed within safe limits to achieve desired results without undue risk.
Phase 2 study medical
"demonstrated improved outcomes across all efficacy endpoints in a Phase 2 study"
A phase 2 study is a mid-stage clinical trial that tests whether an experimental drug or treatment actually works for the intended condition and continues to check safety in a larger group of patients than early trials. Think of it as a focused pilot test before a full market launch; positive or negative results strongly affect a drug’s chances of approval, the remaining development time and costs, and therefore an investment’s risk and potential value.
FAQ
What did PPBT announce in this Form 6-K?
Purple Biotech announced that the U.S. Patent and Trademark Office issued a Notice of Allowance for a patent application covering tri-specific antibody constructs and methods of use that support its CAPTN-3 platform for conditionally activated multispecific antibodies.
How does the new U.S. patent allowance affect PPBT’s CAPTN-3 platform?
The allowance strengthens protection for the modular architecture underlying CAPTN-3, a platform designed to generate tri-specific antibodies by swapping tumor-associated antigen binding domains and functional components, supporting future development and partnering potential for multiple oncology candidates.
What stage are Purple Biotech’s lead CAPTN-3 candidates IM1240 and IM1305?
The CAPTN-3 platform’s lead candidate IM1240 is described as advancing toward the clinic, and its second candidate IM1305 is in preclinical development, both built on the conditionally activated multispecific antibody platform.
Which additional clinical-stage assets are in Purple Biotech’s pipeline (PPBT)?
Purple Biotech’s pipeline includes CM24, a CEACAM1-blocking antibody that showed improved outcomes across all efficacy endpoints in a Phase 2 pancreatic ductal adenocarcinoma study, and NT219, a dual IRS1/2 and STAT3 inhibitor that completed a Phase 2 study in head and neck cancer.
What does a Notice of Allowance from the USPTO mean for PPBT?
A Notice of Allowance indicates the USPTO has determined the allowed claims meet patentability requirements, subject to payment of required issue fees, thereby further strengthening Purple Biotech’s intellectual property protection for its CAPTN-3 platform.
What is the focus of Purple Biotech’s CAPTN-3 platform?
CAPTN-3 is a platform of masked tri-specific antibodies that simultaneously target tumors and engage T cells and NK cells. Its capping technology confines immune activation to the tumor microenvironment, aiming to expand the therapeutic window versus conventional T-cell engagers.
AI-generated analysis. How Rhea-AI works. Not financial advice.
